Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $3,646.

  • bioAffinity Technologies' Cash from Investing Activities rose 138.75% to $3,646 in Q3 2025 from the same period last year, while for Sep 2025 it was -$60,568, marking a year-over-year increase of 7.73%. This contributed to the annual value of -$79,083 for FY2024, which is 96.42% up from last year.
  • bioAffinity Technologies' Cash from Investing Activities amounted to $3,646 in Q3 2025, which was up 127.15% from -$13,427 recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Cash from Investing Activities peaked at $13,442 during Q4 2023, and registered a low of -$2.2 million during Q3 2023.
  • Its 3-year average for Cash from Investing Activities is -$213,550, with a median of -$13,427 in 2025.
  • In the last 5 years, bioAffinity Technologies' Cash from Investing Activities slumped by 632.58% in 2024 and then spiked by 138.75% in 2025.
  • Over the past 3 years, bioAffinity Technologies' Cash from Investing Activities (Quarterly) stood at $13,442 in 2023, then plummeted by 100.01% to -$1 in 2024, then soared by 138.75% to $3,646 in 2025.
  • Its Cash from Investing Activities was $3,646 in Q3 2025, compared to -$13,427 in Q2 2025 and -$50,786 in Q1 2025.